+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prevent Meningitis Vaccine Market - Global Forecast 2026-2032- Product Image
Prevent Meningitis Vaccine Market - Global Forecast 2026-2032- Product Image
Sale

Prevent Meningitis Vaccine Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6154854
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Prevent Meningitis Vaccine Market is projected to reach USD 1.31 Billion in 2026. It is expected to continue growing at a CAGR of 8.48%, reaching USD 2.13 Billion by 2032.

Prevent Meningitis Vaccine Market: Executive Overview

Preventive meningitis vaccination reduces the risk of invasive disease caused by several bacterial pathogens, including meningococcal, pneumococcal, and Haemophilus influenzae type b infections. Demand is shaped by national immunization schedules, outbreak preparedness, pediatric coverage, adolescent programs, travel requirements, adult risk groups, and access to routine healthcare. Because disease epidemiology and vaccine recommendations vary by pathogen and age group, market development depends on differentiated public-health strategies rather than a single universal product pathway.

Immunization Policy and Access Are Reshaping the Landscape

The landscape is being transformed by stronger emphasis on life-course immunization, catch-up vaccination, outbreak response, and integration with primary care. Public-health agencies are increasingly focused on closing coverage gaps created by supply interruptions, unequal healthcare access, conflict, migration, and declining confidence in vaccination. Product characteristics such as schedule simplicity, cold-chain requirements, age indications, and suitability for combination programs influence adoption. Procurement systems, evidence requirements, reimbursement policy, and national recommendations remain decisive factors in translating clinical value into population protection.

Artificial Intelligence Improves Surveillance, Targeting, and Operations

Artificial intelligence can strengthen meningitis prevention by improving analysis of surveillance records, laboratory data, immunization registries, and outbreak signals. Predictive tools may help identify communities at elevated risk, prioritize outreach, optimize clinic capacity, and detect potential supply or cold-chain failures. However, these applications require representative data, transparent validation, privacy safeguards, and clinical or public-health oversight. AI should support-not replace-epidemiological investigation, regulatory review, informed consent, and equitable allocation decisions.

Regional Insights: Uneven Burden and Program Maturity

North America generally benefits from established vaccination infrastructure, electronic records, and broad access, while addressing hesitancy, adult-risk coverage, and disparities among underserved communities. Latin America continues to depend on resilient national programs, regional procurement, and catch-up efforts where routine coverage has been disrupted. Europe combines mature schedules with cross-border surveillance and attention to adolescent and risk-based vaccination. The Middle East faces differing epidemiological profiles, mobility patterns, and health-system capacity across countries. Africa remains highly dependent on donor-supported delivery, reliable surveillance, campaign readiness, and expanded access in areas affected by conflict or limited infrastructure. Asia-Pacific contains substantial diversity, ranging from advanced routine systems to settings where cold-chain capacity, financing, and geographic access remain major constraints.

Group Insights: Cooperation Shapes Coverage and Procurement

ASEAN countries can benefit from coordinated surveillance, shared procurement learning, and strategies suited to varied health-system capacities. BRICS members represent diverse disease burdens and manufacturing, financing, and delivery environments, making collaboration relevant to technology access and program resilience. The European Union benefits from aligned evidence practices and cross-border coordination while retaining national responsibility for schedules and reimbursement. G7 members can contribute to research, financing, surveillance, and emergency preparedness. GCC countries generally have strong healthcare infrastructure but must address migrant-population access and regional mobility. NATO members have a shared interest in continuity of immunization and medical preparedness during emergencies, although national vaccination policies remain distinct.

Country Insights: National Schedules and Delivery Capacity Matter

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States have established immunization systems, with ongoing priorities including equitable coverage, adolescent protection, adult risk groups, and confidence in public-health recommendations. Brazil, Mexico, China, India, and Russia operate across large and diverse populations where regional inequality, procurement, surveillance, and continuity of routine services influence outcomes. Country strategies should reflect local pathogen patterns, age-specific recommendations, healthcare access, regulatory requirements, and the ability to sustain high coverage between outbreaks. Comparative interpretation should therefore focus on program design and delivery conditions rather than assuming that a policy effective in one country will transfer directly to another.

Action Priorities for Leaders: Build Resilient, Equitable Immunization Programs

Industry leaders should align development and access strategies with national schedules, clearly defined risk groups, and public-health evidence requirements. Priorities include investing in stable supply and cold-chain resilience, supporting interoperable immunization records, designing outreach for underserved populations, and preparing rapid-response capabilities for localized outbreaks. Partnerships with public-health authorities can improve education and confidence when communications are transparent and culturally appropriate. Organizations should also establish responsible AI governance, monitor real-world safety and effectiveness, and measure access, completion, and equity outcomes alongside commercial performance.

Research Methodology: Evidence-Led Assessment of Prevention Needs

This executive summary uses a structured, qualitative assessment of meningitis prevention vaccination across the required regions, country groups, and countries. The framework considers disease epidemiology, immunization policy, delivery infrastructure, procurement, access barriers, surveillance, public confidence, and emerging technologies. Findings should be validated against current guidance from national immunization authorities, multilateral health organizations, peer-reviewed epidemiology, regulatory documents, and immunization coverage datasets. Because recommendations and pathogen patterns change over time, interpretation should distinguish verified historical evidence from current policy and avoid extrapolating beyond the available data.

Conclusion: Sustainable Coverage Requires Coordinated Public-Health Action

Preventive meningitis vaccination is shaped by the interaction of epidemiology, policy, infrastructure, financing, and public confidence. The most durable progress will come from integrating routine and catch-up immunization, strengthening surveillance, maintaining dependable supply, and targeting communities that remain underserved. Regional and country differences make local evidence essential, while international cooperation can improve preparedness and access. Leaders that combine scientific rigor with equitable delivery and responsible digital innovation will be better positioned to protect populations against preventable meningitis disease.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of serogroup B meningococcal vaccine recommendations for adolescent and adult populations
5.2. Deployment of thermostable meningitis vaccines to improve access in remote and underserved regions
5.3. Integration of digital immunization tracking platforms to enhance meningitis vaccine coverage monitoring
5.4. Development of multivalent conjugate vaccines to target emerging meningococcal serogroups simultaneously
5.5. Collaborations between biotech firms and public health agencies to accelerate novel vaccine adjuvant research
5.6. Rising vaccine hesitancy trends influencing meningitis prevention strategies and community outreach efforts
5.7. Investment in mRNA based meningitis vaccine candidates for rapid response to serogroup outbreaks
5.8. Growing emphasis on adult booster dosing schedules to sustain long term immunity against meningococcal disease
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Prevent Meningitis Vaccine Market, by Vaccine Type
8.1. Introduction
8.2. Conjugate
8.2.1. Group A
8.2.2. Group B
8.2.3. Group C
8.2.4. Group W-135
8.2.5. Group Y
8.3. Multivalent
8.4. Polysaccharide
8.5. Protein Based
9. Prevent Meningitis Vaccine Market, by Age Group
9.1. Introduction
9.2. Adolescents
9.3. Adults
9.4. Infants
9.5. Pediatrics
10. Prevent Meningitis Vaccine Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Diagnostic Centers
10.4. Hospitals
11. Prevent Meningitis Vaccine Market, by Distribution Channel
11.1. Introduction
11.2. Government Centers
11.3. Hospital Pharmacy
11.4. Online Pharmacy
11.5. Retail Pharmacy
12. Americas Prevent Meningitis Vaccine Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Prevent Meningitis Vaccine Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Prevent Meningitis Vaccine Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Pfizer Inc.
15.3.2. GlaxoSmithKline plc
15.3.3. Sanofi S.A.
15.3.4. Serum Institute of India Private Limited
15.3.5. SK bioscience Co., Ltd.
15.3.6. CSL Limited
15.3.7. Bharat Biotech International Limited
15.3.8. Panacea Biotec Limited
15.3.9. Valneva SE
15.3.10. Bavarian Nordic A/S
16. Research AI17. Research Statistics18. Research Contacts19. Research Articles20. Appendix
List of Figures
FIGURE 1. PREVENT MENINGITIS VACCINE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS PREVENT MENINGITIS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS PREVENT MENINGITIS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PREVENT MENINGITIS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC PREVENT MENINGITIS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. PREVENT MENINGITIS VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. PREVENT MENINGITIS VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. PREVENT MENINGITIS VACCINE MARKET: RESEARCHAI
FIGURE 24. PREVENT MENINGITIS VACCINE MARKET: RESEARCHSTATISTICS
FIGURE 25. PREVENT MENINGITIS VACCINE MARKET: RESEARCHCONTACTS
FIGURE 26. PREVENT MENINGITIS VACCINE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PREVENT MENINGITIS VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY GROUP A, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY GROUP A, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY GROUP B, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY GROUP B, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY GROUP C, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY GROUP C, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY GROUP W-135, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY GROUP W-135, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY GROUP Y, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY GROUP Y, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY MULTIVALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY MULTIVALENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY POLYSACCHARIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY POLYSACCHARIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY PROTEIN BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY PROTEIN BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY INFANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY INFANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY GOVERNMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY GOVERNMENT CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PREVENT MENINGITIS VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS PREVENT MENINGITIS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS PREVENT MENINGITIS VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 83. CANADA PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 84. CANADA PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 85. CANADA PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 86. CANADA PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 87. CANADA PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 88. CANADA PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 89. CANADA PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. CANADA PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. CANADA PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. CANADA PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. MEXICO PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 94. MEXICO PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 95. MEXICO PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 96. MEXICO PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 97. MEXICO PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 98. MEXICO PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 99. MEXICO PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. MEXICO PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. MEXICO PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. MEXICO PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. BRAZIL PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 104. BRAZIL PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. ARGENTINA PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 114. ARGENTINA PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 115. ARGENTINA PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 116. ARGENTINA PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 136. UNITED KINGDOM PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 138. UNITED KINGDOM PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 140. UNITED KINGDOM PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. UNITED KINGDOM PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. GERMANY PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 146. GERMANY PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 147. GERMANY PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 148. GERMANY PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 149. GERMANY PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. GERMANY PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. GERMANY PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. GERMANY PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. GERMANY PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. GERMANY PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. FRANCE PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 156. FRANCE PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 157. FRANCE PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 158. FRANCE PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 159. FRANCE PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 160. FRANCE PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 161. FRANCE PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. FRANCE PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. FRANCE PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. FRANCE PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. RUSSIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 166. RUSSIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 167. RUSSIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 168. RUSSIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 169. RUSSIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 170. RUSSIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 171. RUSSIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. RUSSIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. RUSSIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. RUSSIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. ITALY PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 176. ITALY PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 177. ITALY PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 178. ITALY PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 179. ITALY PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. ITALY PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. ITALY PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. ITALY PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. ITALY PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. ITALY PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. SPAIN PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 186. SPAIN PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 187. SPAIN PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 188. SPAIN PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 189. SPAIN PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 190. SPAIN PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 191. SPAIN PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. SPAIN PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. SPAIN PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. SPAIN PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. UNITED ARAB EMIRATES PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 206. SAUDI ARABIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 208. SAUDI ARABIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 210. SAUDI ARABIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. SAUDI ARABIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. SAUDI ARABIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 216. SOUTH AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 218. SOUTH AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 220. SOUTH AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. SOUTH AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. SOUTH AFRICA PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. DENMARK PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 226. DENMARK PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 227. DENMARK PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 228. DENMARK PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 229. DENMARK PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 230. DENMARK PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 231. DENMARK PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. DENMARK PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. DENMARK PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. DENMARK PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. NETHERLANDS PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 236. NETHERLANDS PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 237. NETHERLANDS PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 238. NETHERLANDS PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 239. NETHERLANDS PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 240. NETHERLANDS PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 241. NETHERLANDS PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. NETHERLANDS PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. NETHERLANDS PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. NETHERLANDS PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. QATAR PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 246. QATAR PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 247. QATAR PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 248. QATAR PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 249. QATAR PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 250. QATAR PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 251. QATAR PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. QATAR PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. QATAR PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. QATAR PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. FINLAND PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 256. FINLAND PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 257. FINLAND PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 258. FINLAND PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 259. FINLAND PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 260. FINLAND PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 261. FINLAND PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. FINLAND PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. FINLAND PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. FINLAND PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. SWEDEN PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 266. SWEDEN PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 267. SWEDEN PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 268. SWEDEN PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 269. SWEDEN PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 270. SWEDEN PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 271. SWEDEN PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. SWEDEN PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. SWEDEN PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. SWEDEN PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. NIGERIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 276. NIGERIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 277. NIGERIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 278. NIGERIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 279. NIGERIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 280. NIGERIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 281. NIGERIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. NIGERIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. NIGERIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. NIGERIA PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. EGYPT PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 286. EGYPT PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 287. EGYPT PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 288. EGYPT PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 289. EGYPT PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 290. EGYPT PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 291. EGYPT PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. EGYPT PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. EGYPT PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. EGYPT PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. TURKEY PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 296. TURKEY PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 297. TURKEY PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 298. TURKEY PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 299. TURKEY PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 300. TURKEY PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 301. TURKEY PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. TURKEY PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. TURKEY PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. TURKEY PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. ISRAEL PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 306. ISRAEL PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 307. ISRAEL PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 308. ISRAEL PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 309. ISRAEL PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 310. ISRAEL PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 311. ISRAEL PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. ISRAEL PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. ISRAEL PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 314. ISRAEL PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 315. NORWAY PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 316. NORWAY PREVENT MENINGITIS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 317. NORWAY PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 318. NORWAY PREVENT MENINGITIS VACCINE MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 319. NORWAY PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 320. NORWAY PREVENT MENINGITIS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 321. NORWAY PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 322. NORWAY PREVENT MENINGITIS VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 323. NORWAY PREVENT MENINGITIS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-202

Companies Mentioned

  • Bavarian Nordic A/S
  • Bharat Biotech International Ltd
  • Biological E. Limited
  • Biomed Pvt. Ltd
  • CanSino Biologics Inc
  • Chongqing Zhifei Biological Products Co., Ltd
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • GlaxoSmithKline plc
  • Hualan Biological Engineering Inc
  • Merck & Co., Inc
  • Novartis AG
  • Panacea Biotec Ltd
  • Pfizer Inc
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd
  • Sinovac Biotech Ltd
  • Walvax Biotechnology Co., Ltd

Related Topics

Related Reports

Meningitis Vaccines Market Insights, Competitive Landscape, and Market Forecast - 2033 - Product Image

Meningitis Vaccines Market Insights, Competitive Landscape, and Market Forecast - 2033

  • Report
  • 200 Pages
  • Global
From
Meningitis Vaccines Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

Meningitis Vaccines Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Meningococcal Vaccines Market - Global Forecast 2026-2032 - Product Image

Meningococcal Vaccines Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Meningococcal Vaccines Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User, and Region 2026-2034 - Product Image

Meningococcal Vaccines Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User, and Region 2026-2034

  • Report
  • 147 Pages
  • Global
From
Meningococcal Vaccines - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Meningococcal Vaccines - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.